CoChat
Sign Up
Cited by 1Antifungal resistance and susceptibilityFungal Infections and StudiesIron Metabolism and Disorders

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Reduced serum iron levels predict poor prognosis in pulmonary mucormycosis patients: a prospective, case‒control study

Open access
Luo, Qiongzhen, He, Xinwei, Xu, Jiao, Li, Li, Zhao, Lina, Mu, Xiangdong·2025·Scientific Reports
DOI 10.1038/s41598-025-15186-3PMC PMC12365034

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Pulmonary mucormycosis (PM) and invasive pulmonary aspergillosis (IPA) are both invasive pulmonary fungal infections with similar clinical manifestations. Few studies have focused on the expression of serum iron in patients with PM and IPA. A prospective, case‒control study was conducted between January 2023 and December 2024. Patients diagnosed with PM or IPA were assigned to the PM group or the IPA group, respectively. Clinical data were recorded for all enrolled patients. Serum iron, serum ferritin, unsaturated iron-binding capacity (UIBC), total iron-binding capacity (TIBC), and percentage transferrin saturation levels were determined via an automatic biochemical detector. A total of 58 patients with PM and 49 patients with IPA were enrolled. Nine patients in the PM group and one patient in the IPA group died during hospitalization. The serum iron, UIBC, and TIBC levels in the PM group were significantly lower than those in the IPA group (all p < 0.05). The serum ferritin level was significantly greater in the PM group than in the IPA group (p = 0.021). Binary logistic regression analysis revealed that only the TIBC level was an independent risk factor for PM [OR (95% CI) = 0.892 (0.839-0.947), p < 0.001]. Cox proportional hazards regression analysis revealed that the serum iron concentration [HR (95% CI) = 0.872 (0.784-0.969); p = 0.011] was an independent predictor of mortality risk in PM patients. Lower TIBC levels at admission were associated with a greater risk of PM, and reduced serum iron levels predict poor prognosis in patients with PM. Using IPA patients as controls, we preliminarily revealed aberrant iron metabolism in PM patients.Trial registration: ClinicalTrials.gov ID NCT06495905, Date of registration July 11, 2024 (retrospectively registered).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-025-15186-3

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Comparison of comorbidities between patients with PM and IPA.
Fig. 1 Comparison of comorbidities between patients with PM and IPA.CC BY-NC-ND · PubMed Central
Fig. 2 Histograms comparing the levels of serum iron-related markers in the PM group and IPA group. (A) Serum iron levels in the PM and IPA groups, p = 0.039. (B) Levels of unsaturated iron-binding capacity in the PM and IPA groups, p = 0.023. (C) Total iron-binding capacity in the PM and IPA groups, p < 0.001. (D) Percent transferrin saturation in the PM and IPA groups, p = 0.584. (E) Serum ferritin levels in the PM and IPA groups, p = 0.021.
Fig. 2 Histograms comparing the levels of serum iron-related markers in the PM group and IPA group. (A) Serum iron levels in the PM and IPA groups, p = 0.039. (B) Levels of unsaturated iron-binding capacity in the PM and IPA groups, p = 0.023. (C) Total iron-binding capacity in the PM and IPA groups, p < 0.001. (D) Percent transferrin saturation in the PM and IPA groups, p = 0.584. (E) Serum ferritin levels in the PM and IPA groups, p = 0.021.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 26

  1. Muthu, V. et al. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. Clin. Microbiol. Infect. 27 (4), 538–549. https://doi.org/10.1016/j.cmi.2020.12.035 (2021). · DOI
  2. Pardo, E. et al. Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies. Intensive Care Med. 45 (12), 1732–1741. https://doi.org/10.1007/s00134-019-05789-6 (2019). · DOI
  3. Alqarihi, A., Kontoyiannis, D. P. & Ibrahim, A. S. Mucormycosis in 2023: an update on pathogenesis and management. Front. Cell. Infect. Microbiol. 21, 13: 1254919. https://doi.org/10.3389/fcimb.2023.1254919 (2023). · DOI
  4. Tanwar, M. et al. Comprehensive review on the virulence factors and therapeutic strategies with the aid of artificial intelligence against mucormycosis. ACS Infect. Dis. 10 (5), 1431–1457. https://doi.org/10.1021/acsinfecdis.4c00082 (2024). · DOI
  5. Haas, H. Iron: a key nexus in the virulence of Aspergillus fumigatus. Front. Microbiol. 3, 28. https://doi.org/10.3389/fmicb.2012.00028 (2012). · DOI · Paper page
  6. Alqarihi, A. et al. GRP78 and integrins play different roles in host cell invasion during mucormycosis. mBio 11 (3), e01087–e01020. https://doi.org/10.1128/mBio.01087-20 (2020). · DOI
  7. Pathakumari, B., Liang, G. & Liu, W. Immune defense to invasive fungal infections: A comprehensive review. Biomed. Pharmacother. 130, 110550. https://doi.org/10.1016/j.biopha.2020.110550 (2020). · DOI
  8. Alexander, B. D. et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC. Clin. Infect. Dis. 72 (Suppl 2), S79–S88. https://doi.org/10.1093/cid/ciaa1855 (2021). · DOI
  9. Skiada, A., Pavleas, I. & Drogari-Apiranthitou, M. Epidemiology and diagnosis of mucormycosis: an update. J. Fungi (Basel). 6 (4), 265. https://doi.org/10.3390/jof6040265 (2020). · DOI
  10. Barker, K. R. et al. A practical workflow for the identification of aspergillus, fusarium, mucorales by MALDI-TOF MS: database, medium, and incubation optimization. J. Clin. Microbiol. 60 (12), e0103222. https://doi.org/10.1128/jcm.01032-22 (2022). · DOI
  11. Zhang, M. et al. Pulmonary artery pseudoaneurysm caused by pulmonary mucormycosis. Am. J. Respir Crit. Care Med. 209 (7), 879–880 (2024). · DOI
  12. Singh, A. et al. Lactoferrin, a potential iron-chelator as an adjunct treatment for mucormycosis - A comprehensive review. Int. J. Biol. Macromol. 187, 988–998. https://doi.org/10.1016/j.ijbiomac.2021.07.156 (2021). · DOI
  13. Happacher, I. et al. Fungal siderophore metabolism with a focus on Aspergillus fumigatus: impact on biotic interactions and potential translational applications. Essays Biochem. 67 (5), 829–842. https://doi.org/10.1042/EBC20220252 (2023). · DOI
  14. Nicolás, F. E. et al. Mucorales species and macrophages. J. Fungi (Basel). 6 (2), 94. https://doi.org/10.3390/jof6020094 (2020). · DOI
  15. Stanford, F. A. et al. Expression patterns in reductive iron assimilation and functional consequences during phagocytosis of lichtheimia corymbifera, an emerging cause of mucormycosis. J. Fungi (Basel). 7 (4), 272. https://doi.org/10.3390/jof7040272 (2021). · DOI
  16. Kumar, H. M. et al. Serum iron indices in COVID-19-associated mucormycosis: A case–control study. Mycoses 65 (1), 120–127. https://doi.org/10.1111/myc.13391 (2022). · DOI
  17. Dp, I., Yadhav Ml, K. & Gs, C. Is serum ferritin an early marker for COVID-19-Associated mucormycosis?? Cureus. ; 15(3): e36734. (2023). https://doi.org/10.7759/cureus.36734 · DOI
  18. Pai, V. et al. Rhino-orbito-cerebral mucormycosis: pictorial review. Insights Imaging. 12 (1), 167. https://doi.org/10.1186/s13244-021-01109-z (2021). · DOI
  19. Paidisetty, P. et al. Changing trend of risk factors of mucormycosis including diabetes, acidosis, and serum iron in the second wave of COVID-19. Indian J. Microbiol. 62 (4), 602–609. https://doi.org/10.1007/s12088-022-01038-5 (2022). · DOI
  20. Billesbølle, C. B. et al. Structure of hepcidin-bound Ferroportin reveals iron homeostatic mechanisms. Nature 586 (7831), 807–811. https://doi.org/10.1038/s41586-020-2668-z (2020). · DOI · Paper page
  21. Pasricha, S. R. et al. Iron deficiency. Lancet 16 (10270), 233–248. https://doi.org/10.1016/S0140-6736(20)32594-0 (2021). · DOI · Paper page
  22. Ueda, T. et al. Serum iron: a new predictor of adverse outcomes independently from serum hemoglobin levels in patients with acute decompensated heart failure. Sci. Rep. 11 (1), 2395. https://doi.org/10.1038/s41598-021-82063-0 (2021). · DOI
  23. Shu, J. et al. Elevated serum iron level is a predictor of prognosis in ICU patients with acute kidney injury. BMC Nephrol. 21 (1), 303. https://doi.org/10.1186/s12882-020-01965-9 (2020). · DOI
  24. Yang, Y., Li, Y. & Chen, Z. Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer. BMC Cancer. 23 (1), 1095. https://doi.org/10.1186/s12885-023-11620-9 (2023). · DOI
  25. Lan, P. et al. Preoperative iron status is a prognosis factor for stage II and III colorectal cancer. Int. J. Clin. Oncol. 26 (11), 2037–2045. https://doi.org/10.1007/s10147-021-01995-9 (2021). · DOI
  26. Lan, P. et al. High serum iron level is associated with increased mortality in patients with sepsis. Sci. Rep. 8 (1), 11072. https://doi.org/10.1038/s41598-018-29353-2 (2018). · DOI

Metadata

Authors
Luo, Q., He, X., Xu, J., Li, L., Zhao, L., & Mu, X.
Affiliations
Beijing Tsinghua Chang Gung Hospital (CN)
Corresponding author
Mu, Xiangdong
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2025-08-19
Volume
15
Issue
1
Pages
30395-30395
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/s41598-025-15186-3
PMC
PMC12365034
OpenAlex
W4413329062
Cited by
1
References
3
Citations by year
2026: 1
FWCI
0.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by-nc-nd)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Beijing Hospitals Authority Clinical Medicine Development of special funding support (ZLRK202323)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Keywords
pulmonary mucormycosis, invasive pulmonary aspergillosis, serum iron, total iron binding capacity, serum ferritin, iron metabolism, prognostic factors, mortality risk, invasive pulmonary fungal infection
MeSH terms
Adult, Aged, Female, Ferritins, Humans, Iron, Lung Diseases, Fungal, Male, Middle Aged, Mucormycosis, Prognosis, Prospective Studies, Risk Factors, Biomarkers, Case-Control Studies, Invasive Pulmonary Aspergillosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced serum iron levels predict poor prognosis in pulmonary mucormycosis patients: a prospective, case‒control study. https://app.cochat.ai/papers/10.1038/s41598-025-15186-3
The paper
Luo, Q., He, X., Xu, J., Li, L., Zhao, L., & Mu, X. (2025). Reduced serum iron levels predict poor prognosis in pulmonary mucormycosis patients: a prospective, case‒control study. Scientific Reports. https://doi.org/10.1038/s41598-025-15186-3